Is SNTI or ACXP more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts rate TAOX or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,819.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TAOX or ACXP more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Acurx Pharmaceuticals N/A -153.92% -101.69%

Which has preferable valuation & earnings, ACXP or TVRD?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Tvardi Therapeutics N/A N/A -$18.21M -$3.10 N/A

Is ACXP or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Tvardi Therapeutics N/A -64.17% -43.90%

Which has preferable earnings & valuation, ACXP or CRVO?

CervoMed is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A CervoMed N/A N/A -$26.97M -$3.28 N/A

Acurx Pharmaceuticals (ACXP) Competitors

$1.62 -0.07 (-3.87%)

As of 01:45 PM Eastern

Compare

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

Should you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Celularity (CELU), Senti Biosciences (SNTI), Synaptogenix (TAOX), Tvardi Therapeutics (TVRD), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does Acurx Pharmaceuticals compare to Celularity?

Celularity (NASDAQ:CELU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Celularity had 4 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Celularity and 0 mentions for Acurx Pharmaceuticals. Celularity's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Acurx Pharmaceuticals	Neutral

Celularity has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its share price is 309% less volatile than the broader market.

19.0% of Celularity shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Celularity. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.93	-$91.72M	-$3.33	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Celularity currently has a consensus price target of $6.00, suggesting a potential upside of 600.93%. Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,819.50%. Given Acurx Pharmaceuticals' higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Summary

Celularity beats Acurx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,487.41	-$61.44M	-$1.92	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Acurx Pharmaceuticals' return on equity of -153.92% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Senti Biosciences' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
Acurx Pharmaceuticals	Neutral

Senti Biosciences has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Senti Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 947.12%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,819.50%. Given Acurx Pharmaceuticals' higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Senti Biosciences beats Acurx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,819.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Synaptogenix has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the broader market.

Acurx Pharmaceuticals' return on equity of -153.92% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals has lower revenue, but higher earnings than Synaptogenix. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	94.55	-$28.74M	-$13.28	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Acurx Pharmaceuticals beats Synaptogenix on 9 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Acurx Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 1,819.50%. Tvardi Therapeutics has a consensus target price of $46.17, suggesting a potential upside of 1,470.29%. Given Acurx Pharmaceuticals' higher possible upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 1 mentions for Tvardi Therapeutics and 0 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Tvardi Therapeutics	Neutral

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats Acurx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to CervoMed?

Acurx Pharmaceuticals (NASDAQ:ACXP) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

CervoMed is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A

Acurx Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 1,819.50%. CervoMed has a consensus target price of $22.60, suggesting a potential upside of 685.54%. Given Acurx Pharmaceuticals' higher probable upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Acurx Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
CervoMed	-672.80%	-136.08%	-112.62%

In the previous week, CervoMed had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 1 mentions for CervoMed and 0 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled CervoMed'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
CervoMed	Neutral

Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 35.4% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CervoMed beats Acurx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.94M	$3.30B	$6.45B	$12.12B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-0.40	19.15	23.92	23.81
Price / Sales	N/A	176.25	480.90	87.50
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.78	8.03	10.36	6.75
Net Income	-$7.97M	$23.89M	$3.57B	$337.72M
7 Day Performance	-16.32%	-5.75%	-1.11%	-3.06%
1 Month Performance	-22.73%	2.11%	3.40%	1.59%
1 Year Performance	-76.73%	36.67%	23.87%	27.17%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	2.4291 of 5 stars	$1.62 -3.9%	$31.00 +1,819.5%	-75.8%	$6.94M	N/A	N/A	3	News Coverage
CELU Celularity	1.516 of 5 stars	$1.06 -0.9%	$6.00 +466.0%	-58.1%	$30.68M	$26.55M	N/A	220
SNTI Senti Biosciences	2.3733 of 5 stars	$0.98 +0.4%	$8.75 +789.4%	-74.9%	$30.65M	$20K	N/A	4
TAOX Synaptogenix	0.2756 of 5 stars	$4.02 -4.5%	N/A	N/A	$30.03M	$300K	N/A	4	Positive News Gap Down
TVRD Tvardi Therapeutics	1.618 of 5 stars	$3.17 -1.6%	$53.60 +1,590.9%	-89.9%	$29.74M	N/A	N/A	80	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

How does Acurx Pharmaceuticals compare to Celularity?

Summary

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Summary

How does Acurx Pharmaceuticals compare to Synaptogenix?

Summary

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

How does Acurx Pharmaceuticals compare to Celularity?

Does the media favor CELU or ACXP?

Which has more volatility and risk, CELU or ACXP?

Do insiders & institutionals hold more shares of CELU or ACXP?

Which has better valuation and earnings, CELU or ACXP?

Do analysts rate CELU or ACXP?

Is CELU or ACXP more profitable?

Summary

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Which has preferable valuation and earnings, SNTI or ACXP?

Is SNTI or ACXP more profitable?

Does the media refer more to SNTI or ACXP?

Which has more volatility & risk, SNTI or ACXP?

Do insiders and institutionals believe in SNTI or ACXP?

Do analysts rate SNTI or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Synaptogenix?

Do analysts rate TAOX or ACXP?

Which has more volatility and risk, TAOX or ACXP?

Is TAOX or ACXP more profitable?

Does the media prefer TAOX or ACXP?

Which has higher valuation and earnings, TAOX or ACXP?

Do insiders & institutionals believe in TAOX or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Do analysts rate ACXP or TVRD?

Which has more risk and volatility, ACXP or TVRD?

Is ACXP or TVRD more profitable?

Does the media refer more to ACXP or TVRD?

Do insiders & institutionals hold more shares of ACXP or TVRD?

Which has preferable valuation & earnings, ACXP or TVRD?

Summary

How does Acurx Pharmaceuticals compare to CervoMed?

Which has preferable earnings & valuation, ACXP or CRVO?

Do analysts prefer ACXP or CRVO?

Is ACXP or CRVO more profitable?

Does the media refer more to ACXP or CRVO?

Which has more risk and volatility, ACXP or CRVO?

Do institutionals and insiders hold more shares of ACXP or CRVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools